A novel molecular grading model: Combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 5, 2012, Pages 2229-2234

  Chen, Jun Xing ^a   Deng, Nan ^a   Chen, Xu ^a   Chen, Ling Wu ^a   Qiu, Shao Peng ^a   Li, Xiao Fei ^a   Li, Jia Ping ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

CKi67; Non muscle invasive bladder cancer; Progression; Recurrence; VEGF

Indexed keywords

KI 67 ANTIGEN; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; BLADDER TUMOR; CANCER GRADING; CANCER STAGING; DISEASE COURSE; ENZYME IMMUNOASSAY; FEMALE; FOLLOW UP; HUMAN; INTRAVESICAL DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; STATISTICAL MODEL; SURVIVAL RATE; TUMOR RECURRENCE;

ADMINISTRATION, INTRAVESICAL; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; KI-67 ANTIGEN; MALE; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM GRADING; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84872686421     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.5.2229     Document Type: Article

References (28)

1. Al-Abbasi DS, Al-Janabi AA, Al-Toriahi KM, et al (2009). Expression of VEGF in urinary bladder transitional cell carcinoma in an Iraqi population subjected to depleted uranium: an immunohistochemical study. Appl Immunohistochem Mol Morphol, 17, 307-11.
2. Bryan RT, Zeegers MP, James ND, et al (2010). Biomarkers in bladder cancer. BJU Int, 105, 608-13.
3. Chade DC, Shariat SF, Godoy G, et al (2009). Critical review of biomarkers for the early detection and surveillance of bladder cancer. J Mens Health, 6, 368-82.
4. Cheng L, Neumann RM, Weaver AL, et al (1999). Predicting cancer progression in patients with stage T1 bladder carcinoma. J Clin Oncol, 17, 3182-7.
5. El-Chennawi FA, Auf FA, Metwally SS, et al (2009). Vascular endothelial growth factor, p53, and the H-ras oncogene in Egyptian patients with bladder cancer. World J Gastrointest Oncol, 1, 62-8.
6. Evans CP, Debruyne F, Payne H, et al (2007). Bladder cancer: Management and future directions. Eur Urol Suppl, 6, 365-73.
7. Fauconnet S, Bernardini S, Lascombe I, et al (2009). Expression analysis of VEGF-A and VEGF-B: Relationship with clinicopathological parameters in bladder cancer. Oncol Rep, 21, 1495-504.
8. Gonul II, Akyurek N, Dursun A, et al (2008). Relationship of Ki67, TP53, MDM-2 and BCL-2 expressions with WHO 1973 and WHO/ISUP grades, tumor category and overall patient survival in urothelial tumors of the bladder. Pathol Res Pract, 204, 707-17.
9. Habuchi T, Marberger M, Droller MJ, et al (2005). Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology, 66, 64-74.
10. Hilmy M, Campbell R, Bartlett JM, et al (2006). The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder. Br J Cancer, 95, 1234-8.
11. Kilicarslan AB, Ogus M, Arici C, et al (2003). Clinical importance of vascular endothelial growth factor (VEGF) for papillary thyroid carcinomas. Apmis, 111, 439-43.
12. Klein M, Vignaud JM, Hennequin V, et al (2001). Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab, 86, 656-8.
13. Lebret T, Becette V, Herve JM, et al (2000). Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer. Eur Urol, 37, 654-9.
14. Li R, Heydon K, Hammond ME, et al (2004). Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86-10. Clin Cancer Res, 10, 4118-24.
15. Margulis V, Lotan Y, Karakiewicz PI, et al (2009), Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. J Natl Cancer Inst, 101, 114-9.
16. Margulis V, Shariat SF, Ashfaq R, et al (2006). Ki-67 is an independent predictor of bladder cancer outcome in patients treated with radical cystectomy for organ-confined disease. Clin Cancer Res, 12, 7369-73.
17. M Burger SDAH (2007). Mcm2 predicts recurrence hazard in stage TaT1 bladder cancer more accurately than CK20 Ki67 and histological grade. Br J Cancer, 96, 1711-5.
18. Oka N, Yamamoto Y, Takahashi M, et al (2005). Expression of angiopoietin-1 and-2, and its clinical significance in human bladder cancer. Bju Int, 95, 660-3.
19. Sakamoto S, Ryan AJ, Kyprianou N (2008). Targeting vasculature in urologic tumors: mechanistic and therapeutic significance. J Cell Biochem, 103, 691-708.
20. Santos L, Amaro T, Costa C, et al (2003). Ki-67 index enhances the prognostic accuracy of the urothelial superficial bladder carcinoma risk group classification. Int J Cancer, 105, 267-72.
21. Shirotake S, Miyajima A, Kosaka T, et al (2011). Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer. Urology, 77, e19-25.
22. van der Loos CM, Meijer-Jorna LB, Broekmans ME, et al (2009). Anti-human Vascular Endothelial Growth Factor (VEGF) Antibody Selection for Immunohistochemical Staining of Proliferating Blood Vessels. J Histochem Cytochem, 58, 109-18.
23. van Rhijn BW, Vis AN, van der Kwast TH, et al (2003). Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. J Clin Oncol, 21, 1912-21.
24. van Rhijn BW, Zuiverloon TC, Vis AN, et al (2010). Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. Eur Urol, 58, 433-41.
25. Viale G, Regan MM, Mastropasqua MG, et al (2008). Predictive value of tumor Ki-67 expression in two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Natl Cancer Inst, 100, 207-12.
26. Vidal O, Soriano-Izquierdo A, Pera M, et al (2008). Positive VEGF immunostaining independently predicts poor prognosis in curatively resected gastric cancer patients: results of a study assessing a panel of angiogenic markers. J Gastrointest Surg, 12, 1005-14.
27. Wolman SR, Goldman B, Slovak ML, et al (2007). Aneusomy for detection of bladder cancer recurrence: a Southwest Oncology Group study. Cancer Genet Cytogenet, 176, 22-7.
28. Yurakh AO, Ramos D, Calabuig-Farinas S, et al (2006). Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder. Eur Urol, 50, 506-15; discussion 515.